Bio-Rad to Report First-Quarter 2026 Financial Results on Thursday, April 30, 2026

Bio-Rad to Report First-Quarter 2026 Financial Results on Thursday, April 30, 2026

BIO-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the first quarter of 2026 on Thursday, April 30, 2026, following the close of the market. Management will discuss these results in a conference call scheduled for 2:00 PM Pacific Time (5:00 PM Eastern Time) that day.

To participate, dial (800) 715-9871 within the U.S. or (646) 307-1963 outside the U.S., access code: 9562470. A live webcast of the conference call will also be available in the "Investor Relations" section of the company's website under "Events & Presentations" at investors.bio-rad.com . A replay of the webcast will be available for up to a year.

About Bio-Rad

BIO-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, BIO-Rad operates a global network of research, development, manufacturing, and sales operations with approximately 7,400 employees and $2.6 billion in revenues in 2025. Our customers include universities, research institutions, hospitals, and biopharmaceutical companies, as well as clinical, food safety, and environmental quality laboratories. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit BIO-rad.com.

Investor Contact:
Ruben Argueta, Investor Relations
510-741-6104
ir@bio-rad.com

Media Contact:
Anna Gralinska, Corporate Communications
510-741-6643
cc@bio-rad.com

News Provided by Business Wire via QuoteMedia

BIO
The Conversation (0)
Lexaria Bioscience Corp. (Nasdaq: LEXX)

Lexaria's New Animal Study Aims to Expand Valuable Intellectual Property

Lexaria Bioscience Corp. (Nasdaq: LEXX), (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the engagement of the contract research organization (“CRO”) to execute and report on its 2026 animal Study #1 (GLP-1-A26-1) that will evaluate a number of... Keep Reading...
Lexaria's New Animal Study Aims to Expand Valuable Intellectual Property

Lexaria's New Animal Study Aims to Expand Valuable Intellectual Property

Contracts signed for Animal Study GLP-1-A26-1 KELOWNA, BC / ACCESS Newswire / April 15, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce the engagement of the contract research organization ("CRO")... Keep Reading...
Freegold Advances Golden Summit Toward Pre-Feasibility and Expands Technical Leadership Team

Freegold Advances Golden Summit Toward Pre-Feasibility and Expands Technical Leadership Team

Key HighlightsSix rigs planned (five active; additional rig to commence next month), supporting accelerated drilling timelines~50,000 m infill-focused program to strengthen grade control and support the upcoming Pre-Feasibility Study (PFS)Ongoing metallurgical work targeting higher recoveries &... Keep Reading...
Lexaria Applauds Eli Lilly's Foundayo Drug Approval

Lexaria Applauds Eli Lilly's Foundayo Drug Approval

The number of oral weight-loss / diabetes drug treatments is expanding, increasing demand for the reduction of side effects KELOWNA, BC / ACCESS Newswire / April 7, 2026 / Lexaria Bioscience Corp. (Nasdaq:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is... Keep Reading...
Lexaria Applauds Eli Lilly's Foundayo Drug Approval

Lexaria Applauds Eli Lilly's Foundayo Drug Approval

The number of oral weight-loss / diabetes drug treatments is expanding, increasing demand for the reduction of side effects KELOWNA, BC / ACCESS Newswire / April 7, 2026 / Lexaria Bioscience Corp. (Nasdaq:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is... Keep Reading...

Interactive Chart

Latest Press Releases

Related News